The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Open accessAbstract
Persistent antiphospholipid (aPL) antibodies are occasionally found in subjects without prior history of thromboembolic events (TEs), raising the dilemma of whether to initiate or not a primary thromboprophylaxis. A first TE is considered rare in aPL carriers, but previous studies did not consider the aPL profile nor was the test positivity confirmed in a reference laboratory. In this study, 104 subjects with high-risk aPL profile (positive lupus anticoagulant, anticardiolipin, and anti-β2–glycoprotein I antibodies, triple positivity) confirmed in a reference laboratory, were followed up for a mean of 4.5 years. There were 25 first TEs (5.3% per year): the cumulative incidence after 10 years was 37.1% (95% confidence interval [CI], 19.9%-54.3%). On multivariate analysis, male sex (hazard ratio = 4.4; 95% CI, 1.5-13.1, P = .007) and risk factors for venous thromboembolism (hazard ratio = 3.3; 95% CI, 1.3-8.5, P = .01) were independent predictors for TEs. Aspirin did not significantly affect the incidence of TE. In conclusion, the occurrence of a first TE in carriers of high-risk aPL profile is considerable; it is more frequent among male subjects and in the presence of additional risk factors for venous TE. These data can help in the decision to initiate primary thromboprophylaxis in these subjects.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In 104 asymptomatic carriers of triple-positive antiphospholipid antibodies confirmed in a reference laboratory, first thromboembolic events occurred at 5.3% per year, with a 10-year cumulative incidence of 37.1%. Male sex and venous thromboembolism risk factors independently predicted events, whereas aspirin did not significantly reduce them.
Key findings
- During 469 patient-years of follow-up, there were 25 first thromboembolic events (5.3% per year); cumulative incidence was 9.8% (95% CI, 3.7%-15.9%) at 2 years, 27.3% (95% CI, 17.1%-37.5%) at 5 years, and 37.1% (95% CI, 19.9%-54.3%) at 10 years.
- On multivariate analysis, independent predictors of thromboembolism were male sex (hazard ratio 4.4; 95% CI, 1.5-13.1; P = .007) and presence of risk factors for venous thromboembolism (hazard ratio 3.3; 95% CI, 1.3-8.5; P = .01).
- Aspirin prophylaxis did not significantly affect thromboembolic events on multivariate analysis (hazard ratio 0.5; 95% CI, 0.2-1.5; P = .2); it was close to significance on univariate analysis but did not achieve statistical significance.
- Among the 25 events, there were 12 arterial and 11 venous thromboembolic events, 1 right atrial thrombosis, and 1 renal thrombotic microangiopathy.
Methods
- Multicenter prospective cohort of 104 subjects with high-risk antiphospholipid antibody profile (triple positivity: lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies) on 2 occasions at least 12 weeks apart, without clinical features of antiphospholipid syndrome; triple positivity was confirmed in a reference laboratory. Mean age was 45 years, 79% were female, and mean follow-up was 4.5 years.
- Subjects were seen annually or earlier as clinically indicated; no long-term anticoagulant treatment was prescribed, and short-term low-molecular-weight heparin was given in high-risk thromboembolism scenarios. Data collected included demographic, laboratory, and clinical variables, autoimmune disease, arterial and venous risk factors, and aspirin treatment.
- Kaplan-Meier survival analysis estimated cumulative incidence of thromboembolism; Cox regression survival analysis identified predictors among demographic factors, autoimmune diseases, anticardiolipin isotype, arterial and venous risk factors, and aspirin treatment. Statistical significance was set at P < .05; analyses used SPSS.
Limitations
- The paper does not include a formal limitations section. It states that larger clinical trials are definitely needed to test hypotheses about aspirin and hydroxychloroquine.
- Evident from the text: treatment with aspirin was observational rather than randomized, so confounding by indication cannot be excluded; the cohort had 104 subjects and 25 events, yielding wide confidence intervals for some estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Own result · 7 No full text of the sources · 4 Own interpretation · 3 Own method · 2 Partly supported · 1 Supported so far · 1 Couldn’t confirm · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“that (1.36%) of 125 single aPL positive carriers with a mean age of 41 years (data taken by a recently published study by our group), 15”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Could not verifycites [15] Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study., Ann Rheum Dis sourceExperimental — accuracy not yet measured
The Results and Discussion report an annual thrombosis incidence of 1.86 per 100 patients for the full cohort of 258 aPL carriers. Searches for 125 single-positive carriers and a 1.36% annual rate found no passage reporting that subgroup rate; the overall rate does not establish or contradict it. (LLM, conf=0.73)
plainn = 125- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the higher incidence of TEs recorded in this study may be related to the selection of high-risk aPL-positive population”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Partly supportedcites [15] Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study., Ann Rheum Dis sourceExperimental — accuracy not yet measured
The Analysis of risk factors for thrombosis identifies hypertension and lupus anticoagulant as independent predictors of thrombotic events, supporting the premise that risk profile matters. The Discussion describes this source paper’s own event rate as low and similar to other studies; it does not assess whether selection of a high-risk population explains the higher incidence in the citing study. Page numbers were not available in our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [16] Mok, 2005, Incidence and risk factors of thromboembolism systemic lupus erythematosus: a comparison of three ethnic groups., Arthritis Rheum source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 18 patients treated with hydroxychloroquine, 2 (11%) had a first TE in the follow-up period.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“male sex (hazard ratio ϭ 4.4; 95% CI, 1.5-13.1,P ϭ .007)and the presence of factors predisposing to VTE (hazard ratio ϭ 3.3; 95% CI, 1.3-8.5,P ϭ .01)were found to be independent predictors for clinical events”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plaincorrelationaln = 25 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Aspirin prophylaxis was close to significance in reducing events on univariate analysis but did not achieve statistical significance on multivariate analysis (hazard ratio ϭ 0.5; 95% CI, 0.2-1.5,P ϭ .2)”
- Also stated in: § Abstract · plain
“As-pirin did not significantly affect the incidence of TE.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“27.3% (95% CI, 17.1%-37.5%)after 5 years”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“male sex (hazard ratio ϭ 4.4; 95% CI, 1.5-13.1,P ϭ .007)and the presence of factors predisposing to VTE (hazard ratio ϭ 3.3; 95% CI, 1.3-8.5,P ϭ .01)were found to be independent predictors for clinical events”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plaincorrelationaln = 25 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the cumulative incidence after 10 years was 37.1% (95% confidence interval [CI], 19.9%-54.3%)”
- Also stated in: § Results · plain
“and 37.1% (95% CI, 19.9%-54.3%)after 10 years (Figure 1).”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, 104 subjects with high-risk aPL profile (positive lupus anticoagulant, anticardiolipin, and anti- 2 -glycoprotein I antibodies, triple positivity) confirmed in a reference laboratory, were followed up for a mean of 4.5 years.There were 25 first TEs (5.3% per year)”
- Also stated in: § Results · plain
“During a total follow-up of 469 years, there were 25 TEs (5.3% per year).”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cumulative incidence of TEs was 9.8% (95% confidence interval [CI], 3.7%-15.9%)after 2 years”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 3
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the annual rate (ϳ 0.4%) of first cardiovascular event (including VTE) in normal white population at 35 to 55 years of age, 14”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Partly supportedcites [14] Roger, 2011, Heart disease and stroke statistics: 2011 update. A report from the American Heart Association., Circulation sourceExperimental — accuracy not yet measured
The Cardiovascular Diseases > Incidence section reports 3 first cardiovascular events per 1,000 men annually at ages 35–44, which is close to the claimed 0.4%. It does not give a single rate for a healthy white population aged 35–55. The Venous Thromboembolism > Incidence section reports VTE separately, not as part of that first-event rate; page numbers were not supplied. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“triple positivity (all 3 tests positive) is associated with thrombosis and identifies high-risk patients with aPL syndrome (APS).6,7”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Introduction
What the sources say
- Not checked — no full text of the sourcecites [6] Pengo, 2005, Antibody profiles for the diagnosis of antiphospholipid syndrome., Thromb Haemost source
- Supportedcites [7] Pengo, 2009, Clinical course of high risk patients diagnosed with antiphospholipid syndrome (APS)., J Thromb Haemost source
The Discussion states that patients positive on all three laboratory tests are at higher risk of thrombosis. The Introduction reports a marked association between multiple positivity and thromboembolic events, and the Discussion describes the triple-positive APS cohort as high-risk. Page numbers are not provided in our copy. (LLM, conf=0.93)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Venous thromboembolism (VTE) was diagnosed by compression ultrasonography or venography in case of deep vein thrombosis, and spiral tomography, ventilation-perfusion lung scan, or pulmonary angiography in case of pulmonary embolism.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Outcome events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data can help in the decision to initiate primary thromboprophylaxis in these subjects.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Rests on an assumption: The clinical course of persons carrying a high-risk antiphospholipid antibody profile (triple positivity) is not known.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it is more frequent among male subjects and in the presence of additional risk factors for venous TE”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“That male sex is related to a higher risk for recurrence of VTE among patients with unprovoked deep vein thrombosis is not new.25”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] McRae, 2006, Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis., Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was approved by the local ethics committee of each Thrombosis Center.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“plasma from patients of each center was retested in a reference laboratory (Padua Thrombosis Center).Final inclusion in the cohort required confirmation of LA positivity as well as aCL and anti- 2 GPI antibody positivity (values in the upper 99th percentile of 40 healthy subjects) for the same isotype.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
plainn = 40- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper relies on this without support.
The clinical course of persons carrying a high-risk antiphospholipid antibody profile (triple positivity) is not known.
“The clinical course in persons with high-risk aPL antibody profile (triple positivity) is not known, casting a shadow on the need for primary prophylaxis to avoid TEs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“aPL profiling also involves consideration of antibody titers since higher titers are associated with higher risk [7,8,30,31].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients positive for the combination of LAC, antiβ 2GPI, and anti-CL antibodies,theso-called triple-positive patients, exhibit a high risk for developing a first thrombotic event and recurrence of thrombosis. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“andpatientspositiveforallthree aPLs are identified as individuals at high risk for a first clinical event and for recurrence. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of note is that many studies on triple positivity merely report patients as being positive for LA without assessing dRVVT and APTT results separately [10,[23][24][25][26][27][28][29], or even use only 1 assay [7,8,12].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“it has been demonstrated that asymptomatic persistent carriers of LA and of the other antiphospholipid antibodies have a higher risk of future thromboembolic events [11,12].”
From Lupus Anticoagulant Detection under the Magnifying Glass (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, persistent aPL positivity can also be found in the absence of clinical criteria of APS in patients called 'aPL carriers,' raising the dilemma of initiating or not a primary thromboprophylaxis. 19,20”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
“IgM aCL, GPL units (mean Ϯ SD) 1.42 Ϯ 0.3”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
“The predominant isotype was considered M when IgM aCL value expressed as MPL units exceeded the IgG aCL value (expressed as GPL units).”
Citations
Cites
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Update of the guidelines for lupus anticoagulant detection
PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03555.x · Cited by 1,197
Self-citationGalli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632
Self-citationErkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22663 · Cited by 401
Antibody profiles for the diagnosis of antiphospholipid syndrome
Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., Iliceto, S., & Pengo, V. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-12-0839 · Cited by 318
Self-citationEffect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.
McRae, S., Tran, H., Schulman, S., Ginsberg, J., & Kearon, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69110-1 · Cited by 289
Mok, C. C., Tang, S. S. K., To, C. H., & Petri, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21224 · Cited by 237
(2004) · PubMed · Cited by 218
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis
DE GROOT, P. G., LUTTERS, B., DERKSEN, R. H. W. M., LISMAN, T., MEIJERS, J. C. M., & ROSENDAAL, F. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01485.x · Cited by 205
Cited by
Sorted by citations
Items 301–400 of 462
Matta, B. N., Uthman, I. W., Taher, A. T., & Khamashta, M. A. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.811183 · Cited by 5
Annem, C., & Furie, R. A. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000564 · Cited by 5
Direct-acting oral anticoagulants in antiphospholipid syndrome
Reshetnyak, T. M., & Nurbaeva, K. S. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-708-715 · Cited by 5
Coexistent antiphospholipid syndrome and myeloproliferative neoplasm
Sayar, Z., Nallamilli, S., Efthymiou, M., Lambert, J., & Cohen, H. (2021) · Lupus · doi:10.1177/09612033211021154 · Cited by 5
“No patients were found to be triple aPL-positive, the aPL phenotype considered to be associated with the highest thrombotic risk (37, 38).”
BackgroundDaughety, M. M., Erkan, D., Lockshin, M. D., & Ortel, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00061-7 · Cited by 5
Moore, G. W., Platton, S., Yartey, N., Foxton, E., White, D., & MacDonald, S. G. (2024) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14240 · Cited by 6
“5,6 The preponderance of thrombosis in APS prompts many requests for LA testing after anticoagulant treatment has been initiated, yet the mainstay coagulation assays for LA detection, dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (APTT), are compromised by…”
MethodAvčin, T., & O’Neil, K. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00024-7 · Cited by 5
Tincani, A., Andréoli, L., & Shoenfeld, Y. (2013) · Lara D. Veeken · doi:10.1093/rheumatology/ket394 · Cited by 5
Key Issues at the Forefront of Diagnosis and Testing for Antiphospholipid Syndrome
Qiao, J. C., Bailly, J., & Opie, J. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241306751 · Cited by 4
Gjermeni, D., Anfang, V., Szabó, S., Vetter, H., Venhoff, A. C., Leggewie, S., Hesselbarth, D., Trenk, D., Buechsel, M., Westermann, D., et al. (2024) · Thrombosis Journal · doi:10.1186/s12959-024-00610-x · Cited by 4
Thrombotic antiphospholipid syndrome: From guidelines to clinical management
Paredes, D., Martín‐Iglesias, D., & Ruiz‐Irastorza, G. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.02.010 · Cited by 6
Unresolved issues in the diagnosis and management of thrombotic antiphospholipid syndrome
Arachchillage, D. J., & Laffan, M. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102724 · Cited by 8
Islam, M. A., Alam, F., Sasongko, T. H., Husin, A., Abdullah, S., Gan, S. H., & Wong, K. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012198 · Cited by 4
Dufrost, V., Risse, J., Wahl, D. G., et al. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0676-2 · Cited by 4
“While high risk triple-positive APS patients have a 5% per year thrombosis risk [6], we may hypothesize that RAPS patients would have a lower 1.”
BackgroundA retrospective review of antiphospholipid syndrome from a South Asian country
Mushtaq, M. Z., Ali, S. A., Sattar, Z., Mahmood, S. B. Z., Amber, T., & Riaz, M. (2021) · Archives of Rheumatology · doi:10.46497/archrheumatol.2022.8979 · Cited by 5
Ceccarelli, F., Natalucci, F., Olivieri, G., Pirone, C., Picciariello, L., Orefice, V., Truglia, S., Spinelli, F. R., Alessandri, C., Chistolini, A., et al. (2022) · Biomolecules · doi:10.3390/biom12081088 · Cited by 4
“Furthermore, up to 60% of the enrolled subjects showed a concomitant CTD, prevalently SLE [17,18].”
BackgroundAcute ST-elevation myocardial infarction in a young patient with antiphospholipid syndrome
Gonzalez-Cordero, A. F., Rodriguez, M. R., Parra, B. M. R., Navas, J. C., Mesa-Pabon, M. A., & Franqui-Rivera, H. (2019) · SAGE Open Medical Case Reports · doi:10.1177/2050313x19848597 · Cited by 4
Laboratory Approaches to Test the Function of Antiphospholipid Antibodies
Szabó, G., Antal‐Szalmás, P., Kerényi, A., Pénzes, K., Bécsi, B., & Kappelmayer, J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1730357 · Cited by 5
Gkrouzman, E., Peng, M., Davis‐Porada, J., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24508 · Cited by 7
Köse, R., Vega, J., Burgos, C., & Erkan, D. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152768 · Cited by 3
Saadalla, A. M., & Nandakumar, V. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117761 · Cited by 4
Thrombosis risk in purely obstetric APS
Simioni, P. (2012) · Blood · doi:10.1182/blood-2012-01-398735 · Cited by 3
Genetic causes of stroke in young patients
Firsov, K. V., Котов, А. С., & Бунак, М. С. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119011102 · Cited by 4
RANGING OF ANTIPHOSPOLIPID ANTIBODIES IN THE PATIENTS WITH THROMBOPHILIA AND RECURRENT MISCARRIAGE
Tkachenko, O. Y., Lapin, S. V., Шмонин, А. А., Solovyova, L. N., Бондарева, Е. А., Selkov, S. А., Chepanov, S. V., Тотолян, А. А., & Roggenbuck, D. (2018) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2018-5-753-762 · Cited by 3
Tsiakas, S., Skalioti, C., Kotsi, P., et al. (2020) · Oxford Medical Case Reports · doi:10.1093/omcr/omaa117 · Cited by 3
“showed that even asymptomatic carriers of all three antiphospholipid antibodies had a high incidence of thromboembolic events, raising the question for primary thromboprophylaxis in these subjects [10].”
BackgroundHong, J.-L., Hou, Y.-T., Lin, P., et al. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8090104 · Cited by 3
“The second hit is endothelial injury as a key to the activation of complement and coagulation, which strongly accelerates the formation of a thrombus [4].”
BackgroundSciascia, S., Radin, M., & Schreiber, K. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00045-x · Cited by 3
Definition and Epidemiology of Antiphospholipid Syndrome
Ünlü, O., Domingues, V., de Jesús, G. R., Zuily, S., Espinosa, G., Cervera, R., Levy, R. A., Wahl, D. G., Erkan, D., & Lockshin, M. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_7 · Cited by 4
Antiphospholipid antibody testing - slow progress?
Hughes, G. R. V., & Shoenfeld, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02887.x · Cited by 3
Lakos, G. (2013) · Drug Development Research · doi:10.1002/ddr.21117 · Cited by 3
“…10-year incidence of the first thromboembolic event in a group of patients who were characterized with LAC, aCL, and anti-β2GPI positivity was 37.1% [Pengo et al., 2011], and in another study, thrombotic events reoccurred in 8.3% of a group of APS patients despite anticoagulant therapy [Tarr et…”
BackgroundInfluentialGarcia, D. A., & Lim, W. (2013) · Hematology · doi:10.1182/asheducation-2013.1.681 · Cited by 3
Triple positive antiphospholipid antibody profile in outpatients with tests for lupus anticoagulants
Froom, P., Saffuri-Elias, E., Rozenberg, O., & Barak, M. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0571 · Cited by 3
“Our results suggest that studies predicting recurrent thromboembolic events and perhaps even in asymptomatic carriers [4] might include two functional tests, not only to increase sensitivity [5, 12] but also to consider the possibility of a higher risk of thromboembolic events if both LAC tests are positive.”
BackgroundRand, J. H., & Wolgast, L. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00020-8 · Cited by 3
Prolonged Prothrombin Time After Discontinuing Vitamin K Antagonist
Schellings, M. W. M., de Maat, M. P. M., de Lathouder, S., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.267245 · Cited by 3
“Antiphospholipids”: the more, the worse?
Wahl, D. G. (2018) · Blood · doi:10.1182/blood-2018-03-837831 · Cited by 3
Antiphospholipid syndrome and challenges with direct oral anticoagulants
Booth, S. W., Burton, K., Hunt, B. J., & Desborough, M. (2020) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0080 · Cited by 3
Han, S. H., Park, K. D., & Kim, S. C. (2021) · Medicine · doi:10.1097/md.0000000000028105 · Cited by 3
“[16] Furthermore, several clinical studies have reported that the risk of thrombosis increases parallel with the number of antibodies in patients with APS.”
BackgroundInfluentialTreatment of Non-criteria Manifestations in Antiphospholipid Syndrome
Lopes, M. R. U., Criado, P. R., Parsi, K., Küçükkaya, R. D., Amigo, M., Tektonidou, M. G., & Andrade, D. C. O. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_13 · Cited by 4
Specker, C. (2015) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-014-1459-z · Cited by 3
Sadick, V., Lane, S., Fischer, E., et al. (2018) · Journal of the Intensive Care Society · doi:10.1177/1751143718762343 · Cited by 3
Assessment of thrombophilia in patients with lupus anticoagulant
Pontara, E., Cattini, M. G., Bison, E., Tonello, M., Zen, M., Vicenzetto, C., Giordani, A. S., Baritussio, A., Caforio, A. L. P., & Pengo, V. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109474 · Cited by 2
Self-citationPathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: comment
Pengo, V. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13510 · Cited by 2
“All these observation are supported by clinical studies [10-12] and animal models in which”
ResultSelf-citationDirect-acting oral anticoagulants in antiphospholipid syndrome: A systematic review
Girón-Ortega, J. A., & González, J. A. G. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.03.017 · Cited by 2
Bradáčová, P., Slavík, L., Úlehlová, J., Kriegová, E., Jará, E., Bultasová, L., Friedecký, D., Ullrychová, J., Procházková, J., Hluší, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123329 · Cited by 2
“…of thrombotic events in patients who have laboratory-expressed APS but are not exhibiting clinical manifestations because, according to current guidelines, anticoagulation therapy is not indicated for these patients [1] although they may be at a high risk of future thrombotic events [59–61].”
BackgroundPascali, F. D., Filippova, Y. A., Donadini, M. P., Pengo, V., & Squizzato, A. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109225 · Cited by 3
Self-citationAntiphospholipid Antibodies and Syndrome: Complexities in Diagnosis and Management
Schreiber, K. I., Sciascia, S., & Hunt, B. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_42 · Cited by 2
An update on current management strategies for antiphospholipid syndrome‑related thrombosis
Rossi, A., Colorio, C. C., Puente, D., & Forastiero, R. R. (2014) · Clinical Lipidology · doi:10.2217/clp.13.85 · Cited by 3
Antiphospholipid Syndrome Risk Evaluation
Vilhena, J., Vicente, H., Martins, M. R., et al. (2016) · Advances in intelligent systems and computing · doi:10.1007/978-3-319-31232-3_15 · Cited by 2
Pediatric Antiphospholipid Syndrome
Avčin, T., & Cimaz, R. (2016) · Technical report · doi:10.1016/b978-0-444-63596-9.00018-9 · Cited by 2
Dekeyser, M., Zuily, S., Champigneulle, J., Eschwège, V., Frimat, L., Perret‐Guillaume, C., & Wahl, D. G. (2013) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2013.07.368 · Cited by 2
“[5] Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al.”
BackgroundInfluentialCostedoat-Chalumeau, N., & Morel, N. (2019) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(19)42133-3 · Cited by 2
Yoneda, K., Ueda, Y., Tanimura, K., et al. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03175-8 · Cited by 2
“Above all, β2GPI-dependent aCL and anti-β2GPI antibodies are reported to be key predictors of arterial thrombosis [33, 34].”
BackgroundHeras, C. B., Gómez, A. P., Hajkhan, A. M., et al. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.04.003 · Cited by 2
Ortel, T. L., Erkan, D., & Lockshin, M. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00061-2 · Cited by 2
Antiphospholipid-Syndrom bei Kindern und Jugendlichen
Hedrich, C. M., & Kallinich, T. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-60410-6_39 · Cited by 2
Varju, L., Bagoly, Z., Ajzner, É., Orbán-Kálmándi, R., Kádár, A. Z., Nevelős, J., & Ilonczai, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591029 · Cited by 3
The role of different aPL subpopulations in the lupus anticoagulant phenomenon
Arachchillage, D. J., Efthymiou, M., & Cohen, H. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102784 · Cited by 1
Rand, J. H. (2011) · Blood · doi:10.1182/blood-2011-08-369058 · Cited by 1
¿Se deben tratar preventivamente los pacientes asintomáticos con anticuerpos antifosfolípidos?
Estrada, P., Gómez‐Vaquero, C., Vives, L. L., & Narváez, J. (2012) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2012.09.001 · Cited by 1
Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies
Cuadrado, M. J. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00015-6 · Cited by 1
Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome
Ruiz‐Irastorza, G., Pengo, V., Tektonidou, M. G., Ruiz‐Arruza, I., Cuadrado, M. J., & Khamashta, M. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_11 · Cited by 1
Self-citationThromboses des artères rénales révélant un syndrome des anticorps anti phospholipides
Arache, W., Bahadi, A., & Kabbaj, D. E. (2018) · Pan African Medical Journal · doi:10.11604/pamj.2018.31.150.15677 · Cited by 1
Clinical Aspects of Antiphospholipid Syndrome
Durcan, L., & Petri, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00042-6 · Cited by 1
Murai, C., Sakata, K., Yoshikawa, K., et al. (2020) · Japanese Journal of Oral & Maxillofacial Surgery · doi:10.5794/jjoms.66.8 · Cited by 1
Hoshi, T., Hiraya, D., Sato, A., et al. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29300 · Cited by 1
“Even in asymptomatic carriers of antiphospholipid antibodies, there is a potential risk of thrombosis, especially in high-risk situations such as surgery or hospitalization.(11) If unexplained prolonged APTT was identified by routine laboratory tests, diagnostic tests for the detection of specific antibodies, includin…”
BackgroundPishko, A. M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17745 · Cited by 1
Badr, O. I., Elrefaey, W. A., Abu-Zaid, M. H., & Elmedany, S. H. (2022) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-021-00105-x · Cited by 1
“Re-testing after 3 months is indicated to ensure reliability, especially in cases of an initial triple-positive test [30].”
BackgroundInfluentialAntiphospholipid Syndrome and Stroke
Grimes, K., Klein, A. P., Lalla, R., Morawo, A., Somani, S., Woodward, M. J., & Cole, J. W. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101777 · Cited by 2
Lee, Y., Gu, J. Y., & Kim, H. K. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02675-9 · Cited by 2
“How we treat” clinical dilemmas in antiphospholipid syndrome: A case-based approach
Cecchi, I., Radin, M., Foddai, S. G., Arbrile, M., Barinotti, A., Rubini, E., Morotti, A., Pengo, V., Roccatello, D., & Sciascia, S. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.10.010 · Cited by 1
Self-citationCryptogenic stroke. Part 4: Antiphospholipid syndrome and cancer
Kulesh, A. A., Belopasova, A. V., Demin, D. A., et al. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-186 · Cited by 1
Penglong, T., Boontanvansom, A., Viboonjuntra, P., et al. (2023) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001247 · Cited by 1
An immunogenomic exome landscape of triple positive primary antiphospholipid patients
Guffroy, A., Jacquel, L., Seeleuthner, Y., Paul, N., Poindron, V., Maurier, F., Delannoy, V., Voegeli, A., Zhang, P., Nespola, B., et al. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00255-w · Cited by 1
Saadalla, A. M., Chen, D., Stuart, M., Pruthi, R. K., Heikal, N., Snyder, M. R., Ashrani, A. A., & Seheult, J. N. (2024) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14251 · Cited by 1
“4,5 16 It is also possible that some LACs may not be “ pathogenic ” and may reflect low-affinity, low-avidity and/or low-titer antibodies.”
BackgroundLaboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome
Žigon, P., Mijovski, M. B., Frank‐Bertoncelj, M., Ambrožič, A., Tomšič, M., Hočevar, A., Božič, B., Šemrl, S. S., Kveder, T., & Čučnik, S. (2015) · InTech eBooks · doi:10.5772/61551 · Cited by 1
Volod, O. (2016) · Hematology & Transfusion International Journal · doi:10.15406/htij.2016.02.00027 · Cited by 1
“The reported risk benefits of primary thrombo-prophylaxis in asymptomatic anti-phospholipid carriers are mixed in the literature [4,6,7].”
BackgroundBelolipetskaia, E., Беляева, И. Б., Vi, M., et al. (2017) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov2017937-11 · Cited by 1
Legnani, C., Martini, G., Bertini, M., Agostini, P., Bondanini, F., Cozzi, M. R., Demicheli, M. S. A., Felice, G. D., Novembrino, C., Paoletti, O., et al. (2018) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.1007/s13631-018-0185-y · Cited by 1
Self-citationLavoipierre, V., Talbot, M., Soubrier, C., Marie, B. D. S., Seux, V., Morange, P., Bernit, E., Ebbo, M., Faucher, B., Harlé, J., et al. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.03.170 · Cited by 1
Escaping the catch 22 of lupus anticoagulant testing
Vinholt, P. J., & Just, S. A. (2020) · RMD Open · doi:10.1136/rmdopen-2019-001156 · Cited by 1
Oral anticoagulants in thrombotic antiphospholipid syndrome: Leave the old road for a new trail?
Pengo, V. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.020 · Cited by 1
Self-citationKao, J., Lan, T., & Li, K. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41881 · Cited by 1
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Ortells, L. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.11.012 · Cited by 1
Evaluation of Antiphospholipid Antibodies
Greaves, M. (2013) · Wiley eBooks · doi:10.1002/9781118543467.ch20 · Cited by 1
Classification Criteria for the Antiphospholipid Syndrome
Derksen, R. H. W. M., & Fritsch-Stork, R. D. E. (2014) · Rare diseases of the immune system · doi:10.1007/978-3-319-11044-8_5 · Cited by 1
Hu, C., Li, S., Xie, Z., et al. (2021) · doi:10.22541/au.161925716.61191337/v1 · Cited by 1
HACHULLA, E. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-71447-4.50012-x
Benzing, C., Matia, I., Fuchs, J., et al. (2015) · Gefässchirurgie · doi:10.1007/s00772-015-0028-3
“Da hohe Antikörpertiter einen Risikofaktor für thromboembolische Ereignisse darstellen [11], führt eine Immunsuppression somit möglicherweise zu einem verminderten Auftreten von Gefäßverschlüssen.”
BackgroundAntiphospholipid: to test, or not to test, that is the question
Lockshin, M. D. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02892.x
Antiphospholipid Antibody Carriers
Dall’Ara, F., Nalli, C., & Andréoli, L. (2014) · Rare diseases of the immune system · doi:10.1007/978-3-319-11044-8_17
Trends in the Antiphospholipid Syndrome Criteria
Forastiero, R. R. (2013) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000e103
“5 years [5].”
The future of treatment for antiphospholipid syndrome
Willis, R., Harris, E. N., & Pierangeli, S. S. (2014) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.13.73
Chapitre 22 – Syndrome des antiphospholipides
Wahl, D. G., Dekeyser, M., Zuily, S., Eschwège, V., Mohamed, S., Lecompte, T., & Regnault, V. (2015) · HAL · doi:10.1016/b978-2-294-74489-1.00022-x
Literature-based followup recommendations Part 5: Common hematologic problems in oncology patients
Brigden, M. L., Owen, C., & Trinkaus, M. A. (2012)
Task Force Report on “Non-criteria” Antiphospholipid Antibody Tests
Bertolaccini, M. L., Amengual, O., Atsumi, T., Binder, W. L., Kutteh, W. H., de Laat, B., Forastiero, R. R., Lambert, M., Matsubayashi, H., Murthy, V. L., et al. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_8
Hemostatic risk factors for pregnancy-related venous thrombosis
Bergrem, A. (2013) · NORA - Norwegian Open Research Archives
Denas, G., & Pengo, V. (2014) · Rare diseases of the immune system · doi:10.1007/978-3-319-11044-8_11
Self-citation
Metadata
- Authors
- Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., Bison, E., Denas, G., Banzato, A., Padayattil Jose, S., & Iliceto, S.
- Affiliations
- Departments of Clinical Cardiology and
- University of Padua (IT)
- University of Bologna (IT)
- District Hospital, Cremona, Italy;
- University of Perugia (IT)
- University of Cagliari (IT)
- Transfusion Medicine, District Hospital, Merate, Italy; and
- Santa Maria Nuova Hospital (IT)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-10-27
- Volume
- 118
- Issue
- 17
- Pages
- 4714-4718
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1975074770
- Cited by
- 468
- References
- 28
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 35 · 2023: 36 · 2022: 18 · 2021: 41 · 2020: 46 · 2019: 42 · 2018: 39 · 2017: 38 · 2016: 29 · 2015: 23 · 2014: 33 · 2013: 28 · 2012: 28
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- antiphospholipid antibodies, thromboembolic events, lupus anticoagulant, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, triple positivity, venous thromboembolism, aspirin, primary thromboprophylaxis, risk factors, male sex, incidence
- MeSH terms
- Adolescent, Adult, Aged, Disease Susceptibility, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Thromboembolism, Incidence, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Early Diagnosis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
